A Retrospective, Observational Study of RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis

Roche

Status: Completed

Conditions: Rheumatoid Arthritis

Study type: Observational

Funder types: Industry

Identifiers

NCT01921478

ML25271

Details and patient eligibility

About

This retrospective, multi-centre, observational study will assess the daily practice patterns and outcomes of the management of rheumatoid arthritis in patients treated with RoActemra/Actemra (tocilizumab). No actual patient will be enrolled in this study; data will be collected from medical records.

Enrollment: 77 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients, >=18 years of age
• Diagnosed with rheumatoid arthritis and moderate to severe disease activity defined as a DAS28 >=5.1
• Inadequate responder to at least 2 non-biological DMARDs
• Absence of documented erosions at start of RoActemra/Actemra treatment
• Received RoActemra/Actemra treatment for at least 6 months
• Availability of data from at least the RoActemra/Actemra treatment initiation visit and the 6 months visit

Exclusion criteria

• Contraindications for treatment with RoActemra/Actemra

Trial design

77 participants in 1 patient group

Cohort